Pharmacodynamics and Proteomic Analysis of Acalabrutinib Therapy: Similarity of On-Target Effects to Ibrutinib and Rationale for Combination Therapy

Acalabrutinib, a highly selective Bruton’s tyrosine kinase inhibitor, is associated with high overall response rates and durable remission in previously treated chronic lymphocytic leukemia (CLL), however, complete remissions were limited. To elucidate on-target and pharmacodynamic effects of acalab...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leukemia
Hlavní autoři: Patel, Viral Kumar, Lamothe, Betty, Ayres, Mary L., Gay, Jason, Cheung, Jean, Balakrishnan, Kumudha, Ivan, Cristina, Morse, Joshua, Nelson, Mark, Keating, Michael J., Wierda, William G., Marszalek, Joseph R., Gandhi, Varsha
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5871548/
https://ncbi.nlm.nih.gov/pubmed/29099493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2017.321
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky